



**Curriculum Vitae  
Europass**

**Informazioni personali**

Nome(i) / Cognome(i) Edoardo Giovanni Giannini

Indirizzo(i)

Telefono(i)

Cellulare:

Fax

E-mail

Cittadinanza Italiana

Data di nascita

Sesso

**Occupazione  
desiderata/Settore  
professionale**

**Esperienza professionale**

Date 2018 – in corso

Lavoro o posizione ricoperti Professore Ordinario di Gastroenterologia

Principali attività e responsabilità

Nome e indirizzo del datore di lavoro Università degli Studi di Genova (Viale Benedetto XV 6, 16132 Genova)

Tipo di attività o settore Medico

Date 2006 – in corso

Lavoro o posizione ricoperti Medico responsabile corsia uomini e struttura di Day Hospital presso l'U.O.C. Clinica Gastroenterologia con Endoscopia

Principali attività e responsabilità

Nome e indirizzo del datore di lavoro Università degli Studi di Genova (Viale Benedetto XV 6, 16132 Genova)

Tipo di attività o settore Medico

Date 2006 – 2018

Lavoro o posizione ricoperti Dirigente Medico a tempo pieno presso il Di.M.I.

Principali attività e responsabilità

Nome e indirizzo del datore di lavoro Università degli Studi di Genova (Viale Benedetto XV 6, 16132 Genova)

Tipo di attività o settore medico

Date 2006 – in corso

Lavoro o posizione ricoperti Docente del Corso di Dottorato in Medicina Interna, Autoimmunità e Malattie dell'Apparato Digerente

Principali attività e responsabilità

Nome e indirizzo del datore di lavoro Università degli Studi di Genova (Viale Benedetto XV 6, 16132 Genova)

Tipo di attività o settore Medico-didattico

Date 2005 – 2018

Lavoro o posizione ricoperti	Ricercatore Universitario presso il Di.M.I.
Principali attività e responsabilità	
Nome e indirizzo del datore di lavoro	Università degli Studi di Genova (Viale Benedetto XV 6, 16132 Genova)
Tipo di attività o settore	Medico-didattico
Date	2005 – 2008
Lavoro o posizione ricoperti	Professore aggregato in Gastroenterologia e Fisiologia Epatica
Principali attività e responsabilità	
Nome e indirizzo del datore di lavoro	Università degli Studi di Genova (Viale Benedetto XV 6, 16132 Genova)
Tipo di attività o settore	Medico-didattico
Date	2001 – 2005
Lavoro o posizione ricoperti	Responsabile Reparto Clinica Gastroenterologica con Endoscopia
Principali attività e responsabilità	
Nome e indirizzo del datore di lavoro	Università degli Studi di Genova (Viale Benedetto XV 6, 16132 Genova)
Tipo di attività o settore	medico
Date	2001 – 2005
Lavoro o posizione ricoperti	Titolare di contratto a prestazione d'opera intellettuale
Principali attività e responsabilità	
Nome e indirizzo del datore di lavoro	Università degli Studi di Genova (Viale Benedetto XV 6, 16132 Genova)
Tipo di attività o settore	Medico
Date	2000- 2003
Lavoro o posizione ricoperti	Assistente per l'insegnamento di Gastroenterologia
Principali attività e responsabilità	
Nome e indirizzo del datore di lavoro	Università degli Studi di Genova (Viale Benedetto XV 6, 16132 Genova)
Tipo di attività o settore	Medico – didattico
<b>Istruzione e formazione</b>	
Date	<b>1999</b>
Titolo della qualifica rilasciata	Diploma di Specializzazione in Gastroenterologia ed Endoscopia Digestiva
Principali tematiche/competenze professionali possedute	
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Genova
Livello nella classificazione nazionale o internazionale	50/50 con lode
Date	<b>1995</b>
Titolo della qualifica rilasciata	Laurea in Medicina e Chirurgia
Principali tematiche/competenze professionali possedute	
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Genova
Livello nella classificazione nazionale o internazionale	106/110
<b>Capacità e competenze personali</b>	

Madrelingua(e) **Italiano**

Altra(e) lingua(e)

Autovalutazione

Livello europeo (\*)

**Inglese**

Comprensione				Parlato				Scritto	
Ascolto		Lettura		Interazione orale		Produzione orale			
B2	Livello intermedio	B2	Livello intermedio	B2	Livello intermedio	B2	Livello intermedio	B2	Livello intermedio

(\*) [Quadro comune europeo di riferimento per le lingue](#)

Capacità e competenze sociali

BUONE COMPETENZE NELL'AMBITO RELAZIONALE SVILUPPATE GRAZIE AL LAVORO SVOLTO NELLE UNITÀ OPERATIVE DI MEDICINA

Capacità e competenze organizzative

BUONA CAPACITÀ ORGANIZZATIVA E DI PIANIFICAZIONE, DOVUTA, OLTRE ALL'IMPEGO NEL SETTORE MEDICO, ANCHE ALLA FIORENTE ATTIVITÀ DI PUBBLICAZIONE

Capacità e competenze informatiche

Altre capacità e competenze

Patente **B**

**Ulteriori informazioni** **AFFILIAZIONI A SOCIETÀ SCIENTIFICHE ITALIANE ED ESTERE:**

- 1996- Associazione Italiana per lo Studio del Fegato (A.I.S.F.).
- 1999- European Association for the Study of the Liver (E.A.S.L.).
- 2005- Società Italiana di Gastroenterologia (S.I.G.E.).
- 2005- Fellow dell'American College of Gastroenterology (A.C.G.).
- 2005- Collegio Nazionale dei Docenti di Gastroenterologia (UNIGASTRO)

**ATTIVITÀ DI COLLABORAZIONE**

Nel triennio 2005-2008 ha intrattenuto rapporti di collaborazione reciproca, dalla quale sono scaturiti studi pubblicati su riviste internazionali, con le seguenti Istituzioni:

- Università di Vienna (Austria), Prof. Dr. Markus Peck-Radosavljevic;
- Università di Portland (Oregon, USA), Prof. Atif Zaman;
- Università di Indianapolis (Indiana, USA), Prof. Naga Chalasani;
- Università di Denver (Arizona, USA), Dr. Jay R. Burton Jr;
- Università di Chicago (Illinois, USA), Prof.<sup>ssa</sup> Sunanda V. Kane;
- Università di Padova, Prof.<sup>ssa</sup> Annarosa Floreani.

- Fa parte del gruppo di studio multicentrico Italian Liver Cancer (Ita.Li.Ca).

*-Ha partecipato a studi multicentrici sotto l'egida dell'Associazione Italiana Studio Fegato (A.I.S.F.).*

**HA SVOLTO ATTIVITÀ DI REVIEWER PER LE SEGUENTI RIVISTE SCIENTIFICHE (ULTIMI 5 ANNI):**

- Acta Haematologica,
- Alimentary Pharmacology and Therapeutics,
- American Journal of Epidemiology,
- American Journal of Gastroenterology,
- Annals of Hepatology,
- Biologics: Targets and Therapy,
- BMC Gastroenterology,
- British Journal of Haematology,
- Canadian Medical Association Journal,
- Clinical Gastroenterology and Hepatology,
- Clinical Infectious Diseases,
- Digestive and Liver Disease,
- Drug Discovery Today,
- European Journal of Clinical Epidemiology,
- European Journal of Clinical Investigation,
- European Journal of Clinical Nutrition,
- European Journal of Gastroenterology and Hepatology,
- Free Radical Research,

**Ulteriori informazioni** Nel corso della propria attività scientifica ha pubblicato su riviste internazionali con sistema di *peer-review*:

- 90 *full papers*,
- 9 *reviews*,
- 7 editoriali,
- 29 lettere all'Editore,
- 4 capitoli di libri.
  
- Primo o ultimo autore in 97/135 (72%) pubblicazioni *peer-reviewed*.
- Pubblicazioni negli ultimi 10 anni: 92
- Citazioni normalizzate per età accademica: 187
- Hc-index: 18

#### **ATTIVITÀ DIDATTICA**

##### **CORSO DI LAUREA IN MEDICINA E CHIRURGIA**

###### ***Anni Accademici 2000/2001; 2001/2002; 2002/2003***

Attività di supporto alla didattica per la disciplina "Gastroenterologia" nel Corso Integrato di Malattie dell'Apparato Digerente.

###### ***Anni Accademici 2005/2006; 2006/2007; 2007/2008; 2009/2010; 2010/2011; 2011/2012***

Attribuzione dell'insegnamento di "Gastroenterologia" (Professore Aggregato) del Corso Integrato di "Patologia Integrata Medico Chirurgica Apparato Gastroenterico".

##### **CORSO DI LAUREA IN SCIENZE INFERMIERISTICHE**

###### ***Anni Accademici 2006/2007; 2007/2008; 2008/2009; 2009/2010; 2010/2011; 2011/2012***

Attribuzione dell'insegnamento di "Gastroenterologia" (Professore Aggregato) del Corso Integrato di "Infermieristica Clinica in Medicina e Chirurgia Specialistica".

##### **SCUOLA DI SPECIALIZZAZIONE IN GASTROENTEROLOGIA ED ENDOSCOPIA DIGESTIVA**

###### ***Anno Accademico 2000/2001***

Attività di supporto alla didattica per la disciplina "Gastroenterologia".

###### ***Anni Accademici 2001/2002; 2002/2003; 2003/2004; 2004/2005***

Contratto di prestazione d'opera intellettuale (articolo 32 dello Statuto dell'Università di Genova, "Professore a contratto") per lo svolgimento del corso di "Semeiotica Funzionale Epato-biliare", integrativo del corso ufficiale di "Clinica Gastroenterologica".

**SCUOLA DI SPECIALIZZAZIONE IN GASTROENTEROLOGIA**

***Anni Accademici 2005/2006; 2006/2007; 2007/2008***

Attribuzione dell'insegnamento di "Fisiopatologia Epatica" (Professore Aggregato).

***Anni Accademici 2006/2007; 2007/2008; 2008/2009; 2009/2010; 2010/2011; 2011-2012***

Attribuzione dell'insegnamento di "Gastroenterologia (Clinica delle Malattie Digestive III + Semeiotica Funzionale e Strumentale Gastroenterologica III)" (Professore Aggregato).

**SCUOLA DI SPECIALIZZAZIONE IN MALATTIE DELL'APPARATO RESPIRATORIO**

***Anni Accademici 2010/2011; 2011/2012***

Attribuzione dell'insegnamento di "Gastroenterologia" (Professore Aggregato).

**Ulteriori informazioni** **SCUOLA DI SPECIALIZZAZIONE IN NEFROLOGIA**

**Anni Accademici 2011/2012**

Attribuzione dell'insegnamento di "Gastroenterologia" (Professore Aggregato).

**DOTTORATO DI RICERCA**

**Cicli dal XXII (2007-2009) al XXVI (2012-2014)**

Docente del Corso di Dottorato in Medicina Interna, Autoimmunità e Malattie dell'Apparato Digerente afferente alla Scuola di Dottorato di Ricerca in Medicina Interna Clinico-Sperimentale avente sede amministrativa presso l'Università degli Studi di Genova.

Membro effettivo del Comitato dei Docenti della Scuola di Dottorato di Ricerca in Medicina Interna Clinico-Sperimentale avente sede amministrativa presso l'Università degli Studi di Genova (Cicli XXII, XXIII, XXIV, XXV, XXVI).

**MASTER UNIVERSITARIO DI II LIVELLO**

**Anni Accademici 2004/2005; 2005/2006; 2006/2007; 2007/2008; 2008/2009; 2009/2010; 2010/2011; 2011/2012**

Docente del Master Universitario di II livello in Emostasi e Trombosi dell'Università degli Studi di Genova (dall'istituzione al corrente Anno Accademico).

**ATTIVITÀ SCIENTIFICA**

**INCARICHI RICEVUTI IN QUALITÀ DI ESPERTO DA ISTITUZIONI ITALIANE ED ESTERE:**

- Membro della European Commission Experts' Database for the Research Framework Programmes (Sixth Research Framework Programme, FP6).
- Membro della European Commission Experts' Database for the Research Framework Programmes (Seventh Research Framework Programme, FP7).
- Reviewer per la Research Foundation Flanders (Belgio) in merito ad *applications* per Post-Doctoral Fellowship e Senior Clinical Investigator.
- Membro dei Revisori per conto della Health Information Research Unit della McMaster University (Canada), progetto McMaster Plus Project.
- Revisore "peer" nella valutazione di prodotti di ricerca conferiti alla Valutazione della Qualità della Ricerca - VQR 2004-2010 (GEV 05).
- Revisore "peer" nella valutazione di prodotti di ricerca conferiti alla Valutazione della Qualità della Ricerca - VQR 2004-2010 (GEV 06).

**AFFILIAZIONI A SOCIETÀ SCIENTIFICHE ITALIANE ED ESTERE:**

- 1996- Associazione Italiana per lo Studio del Fegato (A.I.S.F.).
- 1999- European Association for the Study of the Liver (E.A.S.L.).
- 2005- Società Italiana di Gastroenterologia (S.I.G.E.).
- 2005- Fellow dell'American College of Gastroenterology (A.C.G.).
- 2005- Collegio Nazionale dei Docenti di Gastroenterologia (UNIGASTRO).
- 2012- American Association for the Study of the Liver (AASLD).

**HA SVOLTO ATTIVITÀ DI REVIEWER PER LE SEGUENTI RIVISTE SCIENTIFICHE**

- Acta Haematologica,
- Acta Gastro-enterologica Belgica,
- Anti-Cancer Drugs,
- Alimentary Pharmacology and Therapeutics,
- American Journal of Epidemiology,

## REALTIME MEETING<sup>SRL</sup>

- American Journal of Gastroenterology,
- Annals of Hepatology,
- Biologics: Targets and Therapy,
- BMC Gastroenterology,
- British Journal of Haematology,
- Canadian Medical Association Journal,
- Clinical and Experimental Immunology,
- Clinical Gastroenterology and Hepatology,
- Clinical Infectious Diseases,
- Digestive Diseases and Sciences,
- Digestive and Liver Disease,
- Drug Discovery Today,



**Ulteriori informazioni**

- European Journal of Cancer,
- European Journal of Clinical Epidemiology,
- European Journal of Clinical Investigation,
- European Journal of Clinical Nutrition,
- European Journal of Gastroenterology and Hepatology,
- European Radiology,
- Free Radical Research,
- Gut,
- Helicobacter,
- Hepatology,
- Hepatology International,
- International Journal of Evidence-Based Healthcare,
- Journal of Breath Research,
- Journal of Clinical Gastroenterology,
- Journal of Clinical Outcomes,
- Journal of Experimental & Clinical Cancer Research,
- Journal of Gastroenterology and Hepatology,
- Journal of Gastrointestinal and Liver Diseases,
- Journal of General Internal Medicine,
- Journal of Hepatology,
- Journal of Medical Virology,
- Journal of Pharmacy and Pharmacology,
- Journal of Thrombosis and Haemostasis,
- Journal of Viral Hepatitis,
- Liver International,
- Liver Transplantation,
- Nutrition Research,
- Saudi Medical Journal,
- Scandinavian Journal of Gastroenterology,
- The Lancet,
- The Oncologist,
- Transplantation,
- Tumor Biology,
- World Journal of Gastroenterology.

**ATTIVITÀ EDITORIALE**

- Membro dell'Editorial Board del *World Journal of Gastroenterology* (2004-2006; 2007-2009; 2010-2013).
- Membro dell'Editorial Board di *Gastroenterology Research and Practice* (2009-).
- Membro dell'Editorial Board di *Journal of Gastroenterology and Hepatology Research* (2011-).
- Membro dell'Editorial Board del *World Journal of Hematology* (2011-2015).
- Membro dell'Editorial Board di *Datasets Papers in Medicine – Hepatology* (2012-).
- Membro del Comitato Editoriale del libro di testo del Collegio Nazionale Docenti di Gastroenterologia (UNIGASTRO), edizione 2010-2012.

**ATTIVITÀ DI COLLABORAZIONE**

Ha instaurato rapporti di collaborazione reciproca, dalla quale sono scaturiti studi pubblicati su riviste internazionali, con le seguenti Istituzioni:

- Università di Vienna (Austria), Prof. Markus Peck-Radosavljevic;
- Università di Portland (Oregon, USA), Prof. Atif Zaman;

## REALTIME MEETING<sup>SRL</sup>

- Università di Indianapolis (Indiana, USA), Prof. Naga Chalasani;
  - Università di Denver (Arizona, USA), Dr. Jay R. Burton Jr;
  - Università di Chicago (Illinois, USA), Prof.<sup>SSA</sup> Sunanda V. Kane;
  - Università di Padova, Prof.<sup>SSA</sup> Annarosa Floreani.
  - Department of Medicine, King Fahad Armed Forces Hospital, (Jeddah, Kingdom of Saudi Arabia), Dr. Adnan Agha.
- 
- Fa parte del gruppo di studio multicentrico Italian Liver Cancer (Ita.Li.Ca).
  - Ha partecipato a studi multicentrici sotto l'egida dell'Associazione Italiana Studio Fegato (A.I.S.F.).
  - Primary European Investigator per lo studio di fase III ELEVATE (ELtrombopag EValuated for its Ability to overcome Thrombocytopenia and Enable procedures; ClinicalTrials.gov number, NCT00678587).
  - Primary Italian Investigator per lo studio di fase II SHELTER (A proof-of-concept Phase II study to evaluate efficacy, safety and pharmacokinetics of 4SC-201 and the treatment combination of Sorafenib plus 4SC-201 in patients with hepatocellular carcinoma exhibiting progressive disease under Sorafenib treatment).

**Ulteriori informazioni ATTIVITÀ CLINICA E ASSISTENZIALE**

**1999 –**

Titolare del Servizio di Gastroenterologia dell'Ambulatorio del Centro Storico di Genova dell'Associazione dei Cavalieri Italiani del Sovrano Militare Ordine di Malta (ACISMOM), convenzionato con la Azienda Sanitaria Locale n. 3 "Genovese" della Regione Liguria.

**2002.**

Il 15 marzo 2002 è stato chiamato, in seguito a pubblico concorso, ad assumere servizio in qualità di Dirigente Medico a tempo indeterminato presso l'Unità Operativa Complessa di Gastroenterologia dell'Ospedale Santa Corona di Pietra Ligure (SV), incarico declinato.

**2001-2005**

Medico responsabile presso l'ambulatorio di Gastroenterologia del reparto di Clinica Gastroenterologica con Endoscopia del Dipartimento di Medicina Interna dell'Azienda Ospedaliera Universitaria San Martino di Genova diretto dal Professor Vincenzo Savarino.

**2006 –**

Medico responsabile corsia uomini presso l'Unità Operativa Complessa di Clinica Gastroenterologica con Endoscopia del Dipartimento di Medicina Interna dell'Azienda Ospedaliera Universitaria San Martino di Genova diretta dal Professor Vincenzo Savarino.

**2006 –**

Medico responsabile della struttura di Day-Hospital dell' Unità Operativa Complessa di Clinica Gastroenterologica con Endoscopia del Dipartimento di Medicina Interna dell'Azienda Ospedaliera Universitaria San Martino di Genova diretta dal Professor Vincenzo Savarino.

**ARTICOLI SCIENTIFICI PUBBLICATI PER ESTESO SU RIVISTE INTERNAZIONALI CON SISTEMA DI PEER-REVIEW**

**Articoli**

1. Testa R, Picciotto A, Cagliaris S, Giannini E, Campo N, Alvarez S, Arzani L, Celle G. Effects of Interferon therapy on monoethylglycinexylidide formation in patients with chronic active hepatitis C. *Gastroenterol Intern* 1996; 9: 71-76.
2. Testa R, Cagliaris S, Riso D, Arzani L, Campo N, Alvarez S, Giannini E, Lantieri PB, Celle G. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease. *Am J Gastroenterol* 1997; 92: 2268-2273.
3. Testa R, Campo N, Cagliaris S, Riso D, Alvarez S, Arzani L, Giannini E, Lantieri PB, Celle G. Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis. *Hepato-Gastroenterol* 1998; 45: 154-159.
4. Testa R, Ghia M, Mattioli F, Borzone S, Cagliaris S, Mereto E, Giannini E, Riso D. Effects of reduced glutathione and n-acetylcysteine on lidocaine metabolism in cimetidine treated rats. *Fund Clin Pharmacol* 1998;12: 220-224.
5. Giannini E, Fasoli A, Botta F, Testa R. Wilson's Disease with concomitant  $\square$  Thalassemia and Factor V Deficiency. *Ital J Gastroenterol Hepatol* 1998; 30: 633-635.
6. Giannini E, Botta F, Cagliaris S, Fasoli A, Riso D, Ceppa P, Cresta E, Venturino V, Icardi GC, Lantieri PB, Celle G, Testa R. Chronic liver disease related to hepatitis

- C virus: age of patients seems to be the main determinant of severity independently of viral genotype. *Eur J Gastroenterol Hepatol* 1999; 11: 553-558.
7. Testa R, Valente U, Risso D, Caglieris S, Giannini E, Fasoli A, Botta F, Dardano G, Lantieri PB, Celle G. Can MEGX test and serum bile acids improve prognostic ability of Child-Pugh's score in liver cirrhosis? *Eur J Gastroenterol Hepatol* 1999; 11: 559-563.
- Giannini E, Botta F, Fasoli A, Ceppa P, Risso D, Lantieri PB, Celle G, Testa R. Progressive liver functional impairment is associated to an increase in the AST/ALT ratio. Dig Dis Sci* 1999; 44: 1249-1253.
8. Testa R, Giannini E, Picciotto A, Risso D, Caglieris S, Fasoli A, Lantieri PB, Icardi GC, Lapertosa G, Celle G. Probability of non-response during interferon therapy in patients with chronic hepatitis C. *Hepato-Gastroenterol* 1999; 46: 1928-1936.
- Giannini E, Botta F, Cataldi A, Tenconi GL, Ceppa P, Barreca T, Testa R. Leptin levels in nonalcoholic steatohepatitis and chronic hepatitis C. Hepato-Gastroenterol* 1999; 46: 2422-2425.
9. Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Cresta E, Venturino V, Risso D, Celle G, Testa R. Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients. *Liver* 1999; 19: 432-437.
- Fasoli A, Giannini E, Botta F, Romagnoli P, Testa R. 13CO<sub>2</sub> excretion in breath of normal subjects and cirrhotic patients after 13C-Aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis. Hepato-Gastroenterol* 2000; 47: 234-238.

- Ulteriori informazioni** Testa R, Franceschini R, Giannini E, Cataldi A, Botta F, Fasoli A, Tenerelli P, Rolandi E, Barreca T. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. *J Hepatol* 2000; 33: 33-37.
10. Giannini E, Risso D, Ceppa P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Lantieri PB, Testa R. Utility of alpha glutathione S-transferase assessment in chronic hepatitis C patients with near-normal alanine aminotransferase levels. *Clin Biochem* 2000; 33: 297-301.
  11. Botta F, Giannini E, Fasoli A, Romagnoli P, Risso D, Testa R. The monoethylglycineylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis. *Ther Drug Monit* 2000; 22: 371-374.
  12. Testa R, Giannini E, Ceppa P, Botta F, Romagnoli P, Fasoli A, Risso D. Histological determinants of monoethylglycineylidide formation in patients with chronic hepatitis C. *Ther Drug Monit* 2000; 22: 455-459.
  13. Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa R, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. *Int J Biol Markers* 2000; 15: 226-230.
  14. Cagliaris S, Giannini E, Dardano G, Mondello L, Valente U, Testa R. Tauroursodeoxycholic acid administration as adjuvant therapy in cirrhotic patients on transplantation waiting lists. *Hepato-Gastroenterol* 2000; 47: 1045-1047.
  15. Giannini E, Romagnoli P, Fasoli A, Chiarbonello B, Malfatti F, Botta F, Risso D, Lantieri PB, Savarino V, Testa R. Influence of Helicobacter pylori eradication therapy on 13C-aminopyrine breath test. A comparison among Omeprazole, Lansoprazole, or Pantoprazole containing regimens. *Am J Gastroenterol* 2000; 95: 2762-2767.
  16. Giannini E, Ceppa P, Botta F, Mastracci L, Romagnoli P, Comino I, Pasini A, Risso D, Lantieri PB, Icardi GC, Barreca T, Testa R. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. *Am J Gastroenterol* 2000; 95: 3211-3217.
  17. Giannini E, Arzani L, Borro P, Botta F, Fasoli A, Risso D, Celle G, Testa R. Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? *Hepato-Gastroenterol* 2000; 47: 1395-1398.
  18. Giannini E, Cagliaris S, Ceppa P, Risso D, Lantieri PB, Testa R. Serum procollagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C. *Eur J Gastroenterol Hepatol* 2001; 13: 137-141.
  19. Giannini E, Botta F, Fasoli A, Romagnoli P, Mastracci L, Ceppa P, Comino I, Pasini A, Risso D, Testa R. Increased levels of  $\gamma$ GT suggest the presence of bile duct lesions in patients with chronic hepatitis C. Absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage. *Dig Dis Sci* 2001; 46: 524-529.
  20. Giannini E, Fasoli A, Botta F, Testa E, Romagnoli P, Ceppa P, Testa R. Long-term follow-up of chronic hepatitis C patients after interferon treatment: a functional study. *J Gastroenterol Hepatol* 2001; 16: 399-405.
  21. Giannini E, Mastracci L, Botta F, Romagnoli P, Fasoli A, Risso D, Faravelli F, Ceppa P, Lantieri PB, Icardi GC, Testa R. Liver iron accumulation in chronic hepatitis C patients without HFE mutations: relationships with histological damage, viral load and genotype, and alpha glutathione S-transferase levels. *Eur J Gastroenterol Hepatol* 2001; 13: 1355-1361.
  22. Giannini E, Fasoli A, Borro P, Chiarbonello B, Malfatti F, Romagnoli P, Botta F, Testa E, Fumagalli A, Polegato S, Savarino V, Testa R. Impairment of cytochrome

- P-450 dependent liver activity in cirrhotic patients with *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2001; 15: 1967-1973.
23. Giannini E, Fasoli A, Chiarbonello B, Malfatti F, Romagnoli P, Botta F, Testa E, Polegato S, Fumagalli A, Testa R. 13C-Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. *Aliment Pharmacol Ther* 2002; 16: 717-725.
- Giannini E, Fasoli A, Romagnoli P, Botta F, Fumagalli A, Polegato S, Sola S, Ceppa P, Testa R. Monitoring of liver metabolic function during interferon alpha therapy and its relationship to treatment outcome in chronic hepatitis C patients. Hepato-Gastroenterol* 2002; 49: 778-782.
24. Giannini E, Borro P, Botta F, Fumagalli A, Malfatti F, Podestà E, Romagnoli P, Testa E, Chiarbonello B, Polegato S, Mamone M, Testa R. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. *J Hepatol* 2002; 37: 572-577.
- Giannini E, Botta F, Testa E, Romagnoli P, Polegato S, Malfatti F, Fumagalli A, Chiarbonello B, Risso D, Testa R. The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. Am J Gastroenterol* 2002; 97: 2855-2860.
25. Giannini E, Romagnoli P, Fasoli A, Botta F, Risso D, Testa R. Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. *Age Ageing* 2002; 31: 457-462.
26. Icardi G, Bruzzone B, Gota F, Torre F, Giannini E, Massone L, Li Bassi A, Lai PL, Picciotto A, Ansaldi F. A new assay for hepatitis C virus (HCV) core antigen detection: an alternative to nucleic acid technologies in positive or indeterminate anti-HCV subjects? *Ann Igiene* 2003; 15: 863-870.

- Ulteriori informazioni** *Botta F, Giannini E\*, Romagnoli P, Fasoli A, Malfatti F, Chiarbonello B, Testa E, Risso D, Colla G, Testa R. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003; 52: 134-139. \*I primi due autori condividono l'authorship dell'articolo.*
27. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Ceppa P, Testa R. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. *Arch Intern Med* 2003; 163: 218-224.
  28. Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Ansaldo F, Durando P, Risso D, Lantieri PB, Icardi GC, Testa R. Previous hepatitis B virus infection is associated to worse disease stage, and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus positive patients. *Liver Int* 2003; 23: 12-18.
  29. Giannini E, Fasoli A, Botta F, Romagnoli P, Malfatti F, Chiarbonello B, Mamone M, Savarino V, Testa R. Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. *Dig Dis Sci* 2003; 48: 802-808.
  30. Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podestà E, Romagnoli P, Risso D, Cittadini G, De Caro G. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. *Aliment Pharmacol Ther* 2003; 15: 1563-1569.
  31. Giannini EG, Botta F, Borro P, Risso D, Romagnoli P, Fasoli A, Mele MR, Testa E, Mansi C, Savarino V, Testa R. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. *Gut* 2003; 52: 1200-1205.
  32. Giannini E, Botta F, Borro P, Malfatti F, Fumagalli A, Testa E, Podestà E, Chiarbonello B, Polegato S, Mamone M, Testa R. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. *Am J Gastroenterol* 2003; 98: 2516-2520.
  33. Giannini E, Romagnoli P, Tenconi GL, Botta F, Malfatti F, Chiarbonello B, Mamone M, Barreca T, Testa R. High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: relationship with TNF- $\alpha$  levels. *Dig Dis Sci* 2004; 49: 275-280.
  34. Giannini E, Botta F, Fumagalli A, Malfatti F, Testa E, Chiarbonello B, Polegato S, Bellotti M, Milazzo S, Borgonovo G, Testa R. Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients? *Liver Int* 2004; 24: 465-470.
  35. Giannini E, Risso D, Botta F, Romagnoli P, Malfatti F, Fumagalli A, Testa E, Podestà E, Chiarbonello B, Polegato S, Testa R. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients. A single-centre comparison among four different staging systems. *J Intern Med* 2004; 255: 399-408.
  36. Malfatti F, Giannini E, Emanuela T, Polegato S, Podestà E, Fumagalli A, Cotelessa T, Chiarbonello B, Bellotti M, Botta F, Milazzo S, Testa R. Effects of the association of lansoprazole, clarithromycin and metronidazole for *Helicobacter pylori* eradication therapy, measured by the <sup>13</sup>C Aminopyrine breath test. *Med Sci Monit* 2005; 11: PI 14-18.

37. Giannini EG, Fasoli A, Borro P, Botta F, Malfatti F, Fumagalli A, Testa E, Polegato S, Cotellessa T, Milazzo S, Risso D, Testa R. <sup>13</sup>C-Galactose breath test and <sup>13</sup>C-Aminopyrine breath test for the study of liver function in chronic liver disease. *Clin Gastroenterol Hepatol* 2005; 3: 279-285.

**Giannini EG, Malfatti F, Botta F, Polegato S, Testa E, Fumagalli A, Mamone M, Savarino V, Testa R. Influence of one-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on <sup>13</sup>C-Aminopyrine breath test. *Dig Dis Sci* 2005; 50: 1207-1213.**

38. Giannini EG, Botta F, Borro P, Dulbecco P, Testa E, Mansi C, Savarino V, Testa R. Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: A validation study based on follow-up. *Digest Liver Dis* 2005; 37: 779-785.

**Giannini EG, Risso D, Cagliaris S, Testa R. Longitudinal modifications of the MELD score have prognostic meaning in patients with liver cirrhosis. *J Clin Gastroenterol* 2005; 39: 912-914.**

**Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. A study of four- and seven-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole in patients with treatment-resistant Helicobacter pylori infection. *Aliment Pharmacol Ther* 2006; 23: 281-287.**



Ulteriori informazioni

- Testa E, Malfatti F, Milazzo S, Cordiviola C, Cotellessa T, Marabotto E, Giannini E, Ceppa P, Mamone M, Rizzo D, Testa R. Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease. *Liver Int* 2006; 26: 439-444.
39. Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. Can *Helicobacter pylori* eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of four- and seven-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. *J Clin Gastroenterol* 2006; 40: 515-520.
  40. Giannini EG, Zaman A, Ceppa P, Mastracci L, Rizzo D, Testa R. A simple approach to non-invasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. *J Clin Gastroenterol* 2006; 40: 521-527.
  41. Testa R, Testa E, Giannini E, Borro P, Milazzo S, Isola L, Ceppa P, Lantieri PB, Rizzo D. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. *J Intern Med* 2006; 260: 142-150.
  42. Giannini EG, Savarino V, Testa R. Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastro-oesophageal reflux disease. *Dig Dis Sci* 2006; 51: 1602-1606.
  43. Giannini EG, Zentilin P, Dulbecco P, Iiritano E, Bilardi C, Savarino V, Mansi C, Savarino V. A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. *Dig Dis Sci* 2006; 51: 1904-1909.
  44. Giannini EG, Zaman A, Kreil A, Floreani A, Dulbecco P, Testa E, Sohaey R, Verhey P, Peck-Radosavljevic M, Mansi C, Savarino V, Testa R. Platelet count/spleen diameter ratio for the non invasive diagnosis of esophageal varices. Results of a multi-center, prospective, validation study. *Am J Gastroenterol* 2006; 101: 2511-2519.
  45. Giannini EG, Rizzo D, Testa R, Trevisani F, Di Nolfo MA, Del Poggio P, Benvegnù L, Ludovico Rapaccini G, Farinati F, Zoli M, Borzio F, Caturelli E; Italian Liver Cancer (ITA.LI.CA.) Group. Prevalence and prognostic meaning of the presence of oesophageal varices in patients with hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2006; 4: 1378-1384.
  46. Trevisani F, Magini G, Santi V, Morselli-Labate AM, Cantarini MC, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M; Italian Liver Cancer (ITA.LI.CA) Group. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. *Am J Gastroenterol* 2007; 102: 1022-1031.
  47. Burton JR Jr, Liangpunsakul S, Lapidus J, Giannini E, Chalasani N, Zaman A. Validation of a multivariate model predicting presence and size of varices. *J Clin Gastroenterol* 2007; 41: 609-615.
  48. Trevisani F, Santi V, Gramenzi A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M; Italian Liver Cancer Group. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? *Am J Gastroenterol* 2007; 102: 2448-2457.
  49. Giannini EG, Zentilin P, Dulbecco P, Vigneri S, Scarlata P, Savarino V. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. *Am J Gastroenterol* 2008; 103: 267-275.
  50. Farinati F, Sergio A, Baldan A, Giacomini A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Zoli M, Borzio F, Giannini EG, Caturelli E, Trevisani F. Early and very

- early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. *BMC Cancer* 2009, 9:33.
51. Agha A, Anwar E, Bashir K, Savarino V, Giannini EG. External validation of the platelet count/spleen diameter ratio for the diagnosis of oesophageal varices in hepatitis C virus-related cirrhosis. *Dig Dis Sci* 2009; 54: 654-660.
  52. Basso M, Giannini EG\*, Torre F, Bianchi S, Savarino V, Picciotto A. Elevations in ALT levels late the course of antiviral therapy in HCV-RNA negative patients are associated with virological relapse. *Hepatology* 2009; 49: 1442-1448. \*I primi due autori condividono l'authorship dell'articolo.
  53. Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M; Italian Liver Cancer (ITALICA) Group. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. *Clin Gastroenterol Hepatol* 2009; 7: 580-585.  
*Farinati F, Sergio A, Giacomini A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Zoli M, Borzio F, Giannini EG, Caturelli E, Trevisani F; Italian Liver Cancer group. Is female gender a significant favourable prognostic factor in hepatocellular carcinoma (HCC)? Eur J Gastroenterol Hepatol* 2009; 21: 1212-1218.
  54. Torre F, Basso M, Giannini EG, Feasi M, Boni S, Grasso A, De Leo P, Dodi F, Marazzi MG, Azzola E, Bartolacci V, Percario G, Beltrame A, Borro P, Picciotto A; Ligurian HBV Study Group. Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden. *J Med Virolol* 2009; 81: 1882-1886.

Ulteriori informazioni

55. Parodi A, Dulbecco P, Savarino E, Giannini EG, Bodini G, Corbo M, Isola L, De Conca S, Marabotto E, Savarino V. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared to controls with similar age and gender distribution. *J Clin Gastroenterol* 2009; 43: 962-966.
56. Giannini EG, Torre F, Basso M, Feasi M, Boni S, Grasso A, De Leo P, Dodi F, Marazzi MG, Azzola E, Bartolacci V, Percario G, Beltrame A, Borro P, Savarino V, Picciotto A; Ligurian Hepatitis B Virus Study Group. A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: a region-wide survey in Italy. *J Clin Gastroenterol* 2009; 43: 1001-1007.
57. Giannini EG, Basso M, Savarino V, Picciotto A. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. *J Intern Med* 2009; 266: 537-546.
58. Giannini EG, Bodini G, Corbo M, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA.) group. Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma. *Aliment Pharmacol Ther* 2010; 31: 493-501.
59. Giannini EG, Basso M, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. *Aliment Pharmacol Ther* 2010; 31: 502-508.
60. Mirici-Cappa F, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, Maraldi F, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M, Trevisani F; Italian Liver Cancer Group. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. *Gut* 2010; 59: 387-396.
61. Giannini EG, Basso M, Bazzica M, Contini P, Marengo S, Savarino V, Picciotto A. Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. *J Viral Hepat* 2010; 17: 563-568.
62. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M, Giannini EG, Borzio F, Caturelli E, Chiaramonte M, Bernardi M; Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. *J Hepatol* 2010; 53: 291-297.
63. Giannini EG, Greco A, Marengo S, Andorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. *Clin Gastroenterol Hepatol* 2010; 10: 899-902.
64. Furnari M, Parodi A, Gemignani L, Giannini EG, Marengo S, Savarino E, Assandri L, Fazio V, Bonfanti D, Inferrera S, Savarino V. Clinical Trial: the association between rifaximin and partially hydrolyzed guar gum is more effective than rifaximin alone in eradicating SIBO. *Aliment Pharmacol Ther* 2010; 32: 1000-1006.
65. Giannini EG, Basso M, Savarino V, Picciotto A. Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. *Dig Dis Sci* 2010; 55: 3193-3199.
66. Giannini EG, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA.) group. Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. *Liver Int* 2011; 31: 192-196.
67. Torre F, Giannini EG, Basso M, Fazio V, Savarino V, Picciotto A. Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients. *J Gastrointest Liver Dis* 2011; 20: 47-50.

68. Agha A, Alsaudi D, Furnari M, Abdulhadi Ali MM, Al-Majadah SS, Savarino V, Inferrera S, Giannini EG. Efficacy of 48-hour post-operative antibiotics prophylaxis for patients undergoing percutaneous endoscopic gastrostomy tube in preventing site infection. *J Gastrointest Liver Dis* 2011; 20: 131-134.
69. Vitale A, Morales RR, Zanusi G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiamonte M, Trevisani F, Cillo U; Italian Liver Cancer group. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. *Lancet Oncol* 2011; 12: 654-662.

Ulteriori informazioni

70. Agha A, Abdulhadi MM, Marengo S, Bella A, Alsaudi D, El-Haddad A, Inferrera S, Savarino V, Giannini EG. Use of the platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices in patients with schistosomiasis. *Saudi J Gastroenterol* 2011; 17: 307-311.
71. Farinati F, Giacomini A, Vanin V, Sergio A, Burra P, Cillo U, Di Nolfo A, Del Poggio P, Benvegnu L, Zoli M, Borzio F, Giannini EG, Caturelli E, Cazzagon N, Rapaccini GL, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. *Eur J Gastroenterol Hepatol* 2012; 24: 195-202.
72. Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Bernardi M, Trevisani F. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. *J Hepatol* 2012; 56: 397-405.
73. Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, Rapaccini G, Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Pinna AD; for the Italian Liver Cancer (ITA.LI.CA) Group. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. *J Hepatol* 2012; 56: 1089-1096.
74. Giannini EG, Marengo S, Fazio V, Pieri G, Savarino V, Picciotto A. Peripheral blood cytopenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. *Liver Int* 2012; 32: 1113-1119.
75. Furnari M, Savarino E, Bruzzone L, Moscatelli A, Gemignani L, Giannini EG, Zentilin P, Dulbecco P, Savarino V. Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. *J Gastrointestin Liver Dis* 2012; 21: 157-163.
76. Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D, for the ELEVATE study group. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. *N Engl J Med* 2012; 367: 716-724.
77. Giannini EG, Marengo S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. *Hepatology*, 2012; 56: 1371-1379.
78. Giannini EG, Marengo S, Bruzzone L, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F, for the Italian Liver Cancer (ITA.LI.CA) group. Hepatocellular carcinoma in patients without cirrhosis in Italy. *Digest Liver Dis*, accettato per la pubblicazione.

79.

ARTICOLI COLLABORATIVI

1. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Faggioli S, Almasio PL, on behalf of the Italian Association of the Study of the Liver Disease (AISF)\*. Sustained virological response to interferon- $\alpha$  is associated with improved outcome in HCV-related cirrhosis: A retrospective study. *Hepatology* 2007; 45: 579-587. \*(*Ulteriori Principali Investigatori*: Aghemo A, Amato A, Boccia S, Colloredo G, Cursaro C, De Tullio D, Di Marco V, De Luca M, Fasano M, Giannini E, Gios M, Grattagliano I, Morisco F, Picciotto A, Del Poggio P, Rossi S, Stanzione M, Santoro R, Saracco G, Mazzaro C).
2. Stroffolini T, Almasio PL, Persico M, Bollani S, Benvegnù L, Di Costanzo G, Pastore G, Aghemo A, Stornaiuolo G, Mangia A, Andreone P, Stanzione M, Mazzella G,

- Saracco G, Del Poggio P, Bruno S; Italian Association of the Study of the Liver Disease (AISF)\*. Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. *Am J Gastroenterol* 2008; 103: 1966-1972. \*(*Ulteriori Principali Investigatori*: Giannini E, Morisco F, Picciotto A, Fagioli S, Mazzaro C).
3. Morisco F, Stroffolini T, Medda E, Amoroso DC, Almasio PL, Villa E, Zuin M, Paris B, Stanzione M, Caporaso N; NADIR Study Group.\* Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. *J Viral Hepat* 2010; 17: 427-434. \*(*Ulteriori collaboratori*: Aceti A, Amaddeo G, Ancarani F, Arcuri P, Attili A, Bandiera F, Bellati G, Benigno R, Benini F, Bombardieri G, Bruno S, Capretti A, Carrara M, Cottone C, Cozzolongo R, Demelia L, Di Gaetano G, Esposito P, Fanelli G, Gaeta GB, Giannini EG, Giorgini A, Grieco A, Guadagnino V, Lanzini A, Lo Bello S, Lupo S, Maracci M, Marchi S, Martines D, Mazzella G, Miele L, Milan M, Milani S, Minoli G, Montalto G, Morrone A, Nosotti L, Paroli M, Pastore G, Persico M, Piccinino F, Pinzello GB, Pozzi M, Roffi L, Russello M, Russo M, Sagnelli E, Savarino V, Soccorsi F, Squadrito G, Tabone M, Tarsetti F, Tesini EM, Testa R, Tripi S, Gianfranca S, Vandelli C, Zignego AL).

Ulteriori informazioni REVIEWS

1. Giannini EG, Testa R. <sup>13</sup>C-breath tests and liver fibrosis. *Eur Rev Med Pharmacol Sci* 2004; 8: 51-54.
2. Zentilin P, Dulbecco P, Savarino E, Giannini E, Savarino V. Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux: Literature review. *Digest Liver Dis* 2004; 36: 565-569.
3. Giannini EG, Testa T, Savarino V. Liver enzyme alteration: a guide for clinicians. *Canadian Medical Association Journal* 2005; 172; 367-79.
4. Giannini EG, Kane SV, Testa R, Savarino V. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for “best evidence”? *Digest Liver Dis* 2005; 37: 723-731.
5. Giannini EG, Mansi C, Dulbecco P, Savarino V. Role of partially hydrolysed guar gum in the treatment of irritable bowel syndrome. *Nutrition* 2006; 22: 334-342.
6. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. *Aliment Pharmacol Ther* 2006; 23: 1055-1065.
7. Giannini EG. Review: MRI is more sensitive but less specific than ultrasonography or spiral CT for diagnosis of hepatocellular carcinoma. *American College of Physicians Journal Club* 2006; 145: 21.
8. Giannini EG, Savarino V. Thrombocytopenia in liver disease. *Curr Opin Hematol* 2008; 15: 473-480.
9. Giannini EG, Greco A, Savarino V. A review on the use of eltrombopag in patients with advanced liver disease. *Clinical Medicine: Therapeutics*: <http://www.la-press.com/a-review-on-the-use-of-eltrombopag-in-patients-with-advanced-liver-dis-a1700>.

10.

EDITORIALI

1. Giannini EG, Savarino V. Predictors of pathological severity in non-alcoholic fatty liver disease: Is East meeting West in the middle? *J Gastroenterol Hepatol* 2007; 22: 461-463.
2. Giannini EG. Primary prophylaxis for small esophageal varices PRO: cirrhotic patients with small esophageal varices should undergo primary prophylaxis. *Am J Gastroenterol* 2009; 104: 2132-2134.
3. Giannini EG, Savarino V. Further insights into the causes of thrombocytopenia in chronic hepatitis C. *J Gastrointest Liver Dis* 2010; 19: 357-358.
4. Giannini EG, Savarino V. Epidemiology of thrombocytopenia in chronic hepatitis C patients: more than meets the eye. *J Viral Hepat* 2011; 18: 8-10.
5. Giannini EG. Safety of cardiac surgery in cirrhotic patients: going to the heart of the matter. *Clin Gastroenterol Hepatol* 2012; 10: 350-351.
6. Giannini EG, Erroi V, Trevisani F. Effectiveness of α-fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead? *Expert Rev Gastroenterol Hepatol* 2012; 6: 441-444,
7. Giannini EG. Thrombocytopenia in patients with chronic liver disease: what’s in a name? *Dig Dis Sci*, accettato per la pubblicazione (PMID: 23086124).

LETTERE

1. **Giannini E**, Botta F, Romagnoli P, Testa R. Oral or intravenous lidocaine administration to perform MEGX test. *Dig Dis Sci* 2000; 45: 1011-1012.

2. **Giannini E**, Fasoli A, Botta F, Romagnoli P, Malfatti F, Chiarbonello B, Testa R. Is there a role for multiple quantitative liver function tests? *Dig Liver Dis* 2000; 32: 644.
3. **Giannini E**, Testa R. Is aspartate aminotransferase enough? *Am J Gastroenterol* 2000; 95: 3687-3688.
4. **Giannini E**, Testa R. Chronic hepatitis C in different populations: similar patterns of ALT alteration characterize similar clinical subgroups. *Hepatology* 2001; 33: 313.
5. **Giannini E**, Risso D, Testa R. Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. *Am J Gastroenterol* 2001; 96: 918-919.
6. **Giannini E**, Testa R. Persistently normal aminotransferase in chronic HCV infection: is it time to redefine parameters of "normality"? *Dig Liver Dis* 2001; 33: 202-203.
7. **Giannini E**, Barreca T, Testa R. Leptin in nonalcoholic steatohepatitis: is it one of the "hits"? *Am J Gastroenterol* 2001; 96: 2519-2520.  
*Giannini E, Ceppa P, Testa R. Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy? J Hepatol* 2001; 35: 432-433.
8. **Giannini E**, Testa R. Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have? *Gut* 2002; 51: 456-457.
9. **Giannini E**, Testa R. Can changing counseling strategy change the picture of the chronic hepatitis C patient population? *Arch Intern Med* 2002; 162: 2497.



## Ulteriori informazioni

*Giannini E, Botta F, Testa R. Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. Gastroenterology 2003; 125: 993-994.*

10. **Giannini E**, Testa R. Noninvasive diagnosis of fibrosis: The truth is rarely pure and never simple. *Hepatology* 2003; 35: 1312-1313.
11. **Giannini E**, Testa R. The metabolic syndrome: all criteria are equal, but some criteria are more equal than others. *Arch Intern Med* 2003; 163: 2787-2788.
12. **Giannini E**, Testa R. Non-invasive assessment of liver function: trying not to miss an opportunity. *Aliment Pharmacol Ther* 2004; 19: 827-828.
13. **Giannini EG**, Botta F, Testa R. Prediction of oesophageal varices with platelet count/spleen diameter ratio or platelets alone. *Gut* 2004; 53: 914-915.
14. **Giannini EG**, Testa R. Reply to Farinati et al.: classification of 'intermediate stage', untreated hepatocellular carcinoma patients: the neighbour's grass is not so green. *J Intern Med* 2004; 256: 531.
15. **Giannini EG**, Romagnoli P, Testa R. Eligibility criteria for antiviral therapy in HCV-positive patients: similar things to (almost) similar people. *Am J Gastroenterol* 2006; 101: 406-407.
16. **Giannini EG**, Savarino V. HCV and fat: something is missing. *J Hepatol* 2009; 50: 421-422.
17. **Giannini EG**, Savarino V. Blessed are those who have not seen and yet have believed. *Am J Gastroenterol* 2010; 105: 227-228.
18. **Giannini EG**, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F for the Italian Liver Cancer (ITA.LI.CA.) group. TACE in Child-Pugh class B patients with HCC: between the devil and the deep blue sea. *Liver Int* 2010; 30: 923-924.
19. Marengo S, **Giannini EG**, Savarino V. Patent paraumbilical vein-induced hepatic encephalopathy. *Clin Gastroenterol Hepatol* 2010; 10: A28.
20. **Giannini EG**, Farinati F, Trevisani F. Alpha-fetoprotein in hepatocellular carcinoma surveillance: not wake the dead. *Hepatology* 2011; 54: 376-367.
21. Savarino E, Assandri L, **Giannini EG**, Savarino V. Small intestinal bacterial overgrowth and *Helicobacter pylori* – Can they be cause of thrombocytopenia in patients with chronic liver disease? *Am J Gastroenterol* 2011; 106: 1171-1172.
22. **Giannini EG**, Marengo S, Baldissarro E, Fazio V. Letter to the Editors: IL28B rs 12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin. *Aliment Pharmacol Ther* 2011; 34: 398-400.
23. Abdulhadi–Ali MM, Alsaudi D, Agha A, Ibraheem–Alqahtani N, Furnari M, Savarino V, **Giannini EG**. Full-dose peginterferon alfa-2a and low-dose ribavirin treatment of genotypes 1 and 4 chronic hepatitis C patients with end-stage renal disease. *Clin Gastroenterol Hepatol* 2011; 9: 1004.
24. Farinati F, **Giannini E**, Trevisani F. TACE treatment in hepatocellular carcinoma: what should we do now? *J Hepatol* 2012; 57: 221-222.
25. **Giannini EG**, Savarino V. Comment to: Platelet count/spleen diameter ratio for non-invasive diagnosis of oesophageal varices: Is it useful in compensated cirrhosis? *Digest Liver Dis* 2012; 44: 965.
26. **Giannini EG**, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F, for the Italian Liver Cancer (ITA.LI.CA) group. Ten-year outcome of radiofrequency thermal ablation for hepatocellular carcinoma: an Italian experience. *Am J Gastroenterol* 2012; 107: 1588-1589.
27. **Giannini EG**, Savarino V. Which anticoagulant drug should be used treat portal vein thrombosis in patients with chronic liver disease? *Clin Gastroenterol Hepatol*, accettato per la pubblicazione (PMID: 22902778).

[28. Years of life that could be saved from prevention of hepatocellular carcinoma.](#)

Cucchetti A, Trevisani F, Bucci L, Ravaioli M, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Pinna AD; Italian Liver Cancer Group. *Aliment Pharmacol Ther.* 2016 Apr;43(7):814-24. doi: 10.1111/apt.13554. Epub 2016 Feb 11

[29. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.](#)

Bitzer M, Horgner M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B. *J Hepatol.* 2016 Aug;65(2):280-8. doi: 10.1016/j.jhep.2016.02.043. Epub 2016 Mar 4.

[30. Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.](#)

Grotzinger KM, Younossi ZM, Giannini EG, Chen PJ, Rendas-Baum R, Theodore D. *Health Qual Life Outcomes.* 2016 Mar 22;14:49. doi: 10.1186/s12955-016-0447-1.

[31. Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference.](#)

Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). *Dig Liver Dis.* 2016 May;48(5):455-467. doi: 10.1016/j.dld.2016.02.008. Epub 2016 Feb 27. Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomini A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA.LI.CA study group. *PLoS Med.* 2016 Apr 26;13(4):e1002006. doi: 10.1371/journal.pmed.1002006. eCollection 2016 Apr.

[32. Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease.](#)

Furnari M, Bodini G, Giannini EG, Savarino V. *Aliment Pharmacol Ther.* 2016 Jun;43(11):1240-1. doi: 10.1111/apt.13581. No abstract available

33. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.

Bodini G, Giannini EG, Savarino V, Del Nero L, Pellegatta G, De Maria C, Baldissarro I, Savarino E. *Scand J Gastroenterol.* 2016 Sep;51(9):1081-6. doi: 10.3109/00365521.2016.1157894. Epub 2016 May 20.

33. Positive PET in a Patient With Esophageal Leiomyoma.

Nero LD, Moscatelli A, Fazio V, Pellegatta G, Bongioanni F, Sambuceti G, Savarino V, Giannini EG. *Am J Gastroenterol.* 2016 Jun;111(6):767. doi: 10.1038/ajg.2016.205. No abstract available. Erratum in: *Am J Gastroenterol.* 2017 Jul;112(7):1210.

34. The evolutionary scenario of hepatocellular carcinoma in Italy: an update.

Bucci L, Garuti F, Lenzi B, Pecorelli A, Farinati F, Giannini EG, Granito A, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cammà C, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG,

Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. *Liver Int.* 2017 Feb;37(2):259-270. doi: 10.1111/liv.13204. Epub 2016 Aug 17.

35. Breath Tests to Assess Alcoholic Liver Disease.

Furnari M, Ahmed I, Erpecum KJ, Savarino V, Giannini EG. *Rev Recent Clin Trials.* 2016;11(3):185-90. Review.

36. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Morisco F, Gasbarrini A, Baroni GS, Foschi FG, Biasini E, Masotto A, Virdone R, Bernardi M, Trevisani F; Italian LiverCancer (ITA.LI.CA) group. *Liver Int.* 2017 Mar;37(3):423-433. doi: 10.1111/liv.13242. Epub 2016 Oct 2.

37. [Personalized treatment of patients with very early hepatocellular carcinoma.](#)

Vitale A, Peck-Radosavljevic M, Giannini EG, Vibert E, Sieghart W, Van Poucke S, Pawlik TM. *J Hepatol.* 2017 Feb;66(2):412-423. doi: 10.1016/j.jhep.2016.09.012. Epub 2016 Sep 24. Review.

38. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.

Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, Tovoli F, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Boccaccio V, Craxì A, Bruno S, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) Group. *Aliment Pharmacol Ther.* 2017 Jan;45(1):160-168. doi: 10.1111/apt.13821. Epub 2016 Oct 28.

39. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index.

Bodini G, Giannini EG, De Maria C, Dulbecco P, Furnari M, Marabotto E, Savarino V, Savarino E. *Dig Liver Dis.* 2017 Feb;49(2):175-180. doi: 10.1016/j.dld.2016.10.014. Epub 2016 Nov 2.

40. Isotope effect in superconducting n-doped SrTiO<sub>3</sub>.

Stucky A, Scheerer GW, Ren Z, Jaccard D, Poumirol JM, Barreteau C, Giannini E, van der Marel D. *Sci Rep.* 2016 Nov 28;6:37582. doi: 10.1038/srep37582.

41. Noninvasive assessment of varices needing treatment in patients with advanced chronic liver disease: No one should be left behind.

Giannini EG, Savarino V. *Hepatology.* 2017 Jun;65(6):2131. doi: 10.1002/hep.29087. Epub 2017 Apr 24. No abstract available.

42. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.

Cabibbo G, Petta S, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, Negrini G, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Mega A, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Craxì A, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) group. *J Hepatol.* 2017 Jul;67(1):65-71. doi: 10.1016/j.jhep.2017.01.033. Epub 2017 Feb 10.

43. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.

Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. *Lancet Gastroenterol Hepatol.* 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10.

44. Erratum: Positive PET in a Patient With Esophageal Leiomyoma.

Del Nero L, Moscatelli A, Fazio V, Pellegatta G, Bongioanni F, Sambuceti G, Savarin V, Giannini EG. *Am J Gastroenterol.* 2017 Jul;112(7):1210. doi: 10.1038/ajg.2017.153. Epub 2017 May 30.

45. A Liver Index and its Relationship to Indices of HCC Aggressiveness.

Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Masotto A, Trevisani F. *J Integr Oncol.* 2016 Oct;5(4). pii: 178. doi: 10.4172/2329-6771.1000178. Epub 2016 Sep 5.

46. A Nodule, is a Nodule, is a Nodule: May Alpha-Fetoprotein Make the Difference?

Giannini EG, Bodini G, Savarino V. *Am J Gastroenterol.* 2017 Aug;112(8):1340. doi: 10.1038/ajg.2017.128. No abstract available

47. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.

Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammarino A, Raimondo G, Filomia R, Coppola C, Amoruso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonna S, Cannizzaro M, Zignego AL, Monti M, Russo FP, Zanetto A, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M, Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, Giannini EG. *PLoS One.* 2017 Oct 4;12(10):e0185728. doi: 10.1371/journal.pone.0185728. eCollection 2017.

48. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.  
Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. *Hepatology*. 2018 May;67(5):1784-1796. doi: 10.1002/hep.29668. Epub 2018 Apr 6.
49. Editorial: a step forward in refining prognostication for patients with HIV-associated hepatocellular carcinoma.  
Giannini EG. *Aliment Pharmacol Ther*. 2018 Jan;47(1):133-134. doi: 10.1111/apt.14374. No abstract available.
50. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease.  
Bodini G, Giannini EG, Savarino V, Del Nero L, Lo Pumo S, Brunacci M, De Bortoli N, Jain A, Tolone S, Savarino E. *Dig Liver Dis*. 2018 May;50(5):452-456. doi: 10.1016/j.dld.2017.11.008. Epub 2017 Nov 27.
51. High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.  
Mor-Vaknin N, Rivas M, Legendre M, Mohan S, Yuanfan Y, Mau T, Johnson A, Huang B, Zhao L, Kimura Y, Spalding SJ, Morris PW, Gottlieb BS, Onel K, Olson JC, Edelheit BS, Shishov M, Jung LK, Cassidy EA, Prahalad S, Passo MH, Beukelman T, Mehta J, Giannini EH, Adams BS, Lovell DJ, Markovitz DM. *Arthritis Rheumatol*. 2018 Apr;70(4):594-605. doi: 10.1002/art.40404. Epub 2018 Feb 22.
52. Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group.  
Vitale A, Lai Q, Farinati F, Bucci L, Giannini EG, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Pawlik TM; Italian Liver Cancer (ITA.LI.CA) group. *J Gastrointest Surg*. 2018 May;22(5):859-871. doi: 10.1007/s11605-018-3688-y. Epub 2018 Jan 19.
53. Ponziani FR, Miele L, Tortora A, Furnari M, Bodini G, Pompili M, Gasbarrini A, Giannini EG.  
*Expert Rev Clin Pharmacol*. 2018 May;11(5):519-524. doi: 10.1080/17512433.2018.1447923. Epub 2018 Mar 9. Review.
54. Ponziani FR, Miele L, Tortora A, Furnari M, Bodini G, Pompili M, Gasbarrini A, Giannini EG.

Expert Rev Clin Pharmacol. 2018 May;11(5):519-524. doi: 10.1080/17512433.2018.1447923. Epub 2018 Mar 9. Review.

55. Specific issues concerning the management of patients on the waiting list and after liver transplantation.

Burra P, Giannini EG, Caraceni P, Ginanni Corradini S, Rendina M, Volpes R, Toniutto P. *Liver Int.* 2018 Aug;38(8):1338-1362. doi: 10.1111/liv.13755. Epub 2018 May 16. Review.

56. Metabolic disorders across hepatocellular carcinoma in Italy.

Morisco F, Guarino M, Valvano MR, Auriemma F, Farinati F, Giannini EG, Ciccarese F, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Benvenuto L, Gasbarrini A, Svegliati Baroni G, Foschi FG, Biasini E, Masotto A, Viridone R, Marra F, Caporaso N, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. *Liver Int.* 2018 Nov;38(11):2028-2039. doi: 10.1111/liv.13877. Epub 2018 Jun 19.

57. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxi A; ABACUS Study Group. *Infection.* 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28.

58. Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients.

Carr BI, Giannelli G, Guerra V, Giannini EG, Farinati F, Rapaccini GL, Marco MD, Zoli M, Caturelli E, Masotto A, Viridone R, Sacco R, Trevisani F. *Int J Biol Markers.* 2018 Nov;33(4):423-431. doi: 10.1177/1724600818776838. Epub 2018 Jun 6.

59. Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn.

Marabotto E, Furnari M, Giannini EG, Savarino V, Savarino E. *Aliment Pharmacol Ther.* 2018 Jul;48(1):107-108. doi: 10.1111/apt.14800. No abstract available.

60. Correction: Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma.

Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Baroni GS, Viridone R, Masotto A, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. *Am J Gastroenterol.* 2018 Jul;113(7):1100. doi: 10.1038/s41395-018-0131-7.

61. A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients.

Giannini EG, Bodini G, Furnari M, Marabotto E. *Am J Gastroenterol.* 2019 Feb;114(2):364-365. doi: 10.1038/s41395-018-0128-2. No abstract available.

62. Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases.

Carbone F, Bodini G, Brunacci M, Bonaventura A, Vecchiè A, Liberale L, Crespi M, Baldissarro I, Dallegri F, Savarino V, Montecucco F, Giannini EG. *Eur J Clin Invest*. 2018 Oct;48(10):e13002. doi: 10.1111/eci.13002. Epub 2018 Aug 6.

63. Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study.

Vitale A, Farinati F, Noaro G, Burra P, Pawlik TM, Bucci L, Giannini EG, Faggiano C, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Fornari F, Marignani M, Vicari S, Bortolini E, Cozzolongo R, Grasso A, Aliberti C, Bernardi M, Frigo AC, Borzio M, Trevisani F, Cillo U; Italian Liver Cancer (ITA.LI.CA) group. *Hepatology*. 2018 Oct;68(4):1232-1244. doi: 10.1002/hep.30185.

64. Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients.

Giannini EG, Giambruno E, Brunacci M, Plaz Torres MC, Furnari M, Bodini G, Zentilin P, Savarino V. *Ann Hepatol*. 2018 Jun 5;17(5):830-835. doi: 10.5604/01.3001.0012.0775.

65. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis.

Guarino M, Viganò L, Ponziani FR, Giannini EG, Lai Q, Morisco F; Special Interest Group on Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. *Dig Liver Dis*. 2018 Nov;50(11):1105-1114. doi: 10.1016/j.dld.2018.08.001. Epub 2018 Aug 11. Review.

66. Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: The perfect storm.

Giannini EG, Bodini G, Furnari M, Marabotto E. *Liver Int*. 2018 Nov;38(11):2101. doi: 10.1111/liv.13962. Epub 2018 Oct 8. No abstract available.

67. NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis.

Giannini EG, Bodini G, Furnari M, Marabotto E. *J Hepatol*. 2018 Oct;69(4):972-973. doi: 10.1016/j.jhep.2018.05.016. Epub 2018 Jul 4. No abstract available.

68. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.

Furnari M, De Alessandri A, Cresta F, Haupt M, Bassi M, Calvi A, Haupt R, Bodini G, Ahmed I, Bagnasco F, Giannini EG, Casciaro R. *J Gastroenterol*. 2019 Mar;54(3):261-270. doi: 10.1007/s00535-018-1509-4. Epub 2018 Sep 19.

69. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal

medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI). *Infection*. 2019 Feb;47(1):141-168. doi: 10.1007/s15010-018-1209-2. Epub 2018 Sep 25.

70. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI). *J Nephrol*. 2018 Oct;31(5):685-712. doi: 10.1007/s40620-018-0523-1. Epub 2018 Sep 25.

71. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI). *Intern Emerg Med*. 2018 Dec;13(8):1139-1166. doi: 10.1007/s11739-018-1940-9. Epub 2018 Sep 25.

72. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT), the Italian Society of Internal Medicine (SIMI). *Dig Liver Dis*. 2018 Nov;50(11):1133-1152. doi: 10.1016/j.dld.2018.08.022. Epub 2018 Sep 12.

73. Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations.



Crespi M, Ghidotti I, Bodini G, Furnari M, Marabotto E, Giannini EG. Dig Liver Dis. 2019 Jan;51(1):173-174. doi: 10.1016/j.dld.2018.09.025. Epub 2018 Oct 1. No abstract available.

74. Successful DAA Treatment and Global Improvement in a Cirrhotic Patient with Concomitant HCV Infection and Autoimmune Hepatitis.

De Maria C, Ghidotti I, Grillo F, Giannini EG. Dig Dis Sci. 2019 Feb;64(2):591-593. doi: 10.1007/s10620-018-5356-1. Epub 2018 Nov 1. No abstract available.

75. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals.

Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F, Zentilin P, Savarino V. Eur J Clin Invest. 2019 Mar;49(3):e13056. doi: 10.1111/eci.13056. Epub 2018 Dec 19.

76. Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study.

Pinato DJ, Allara E, Chen TY, Trevisani F, Minguez B, Zoli M, Harris M, Dalla Pria A, Merchante N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Farinati F, Rapaccini GL, Aytaman A, Yin M, Tan CK, Bower M, Giannini EG, Bräu N; Liver Cancer in HIV and ITA.LI.CA Study Groups. J Clin Oncol. 2019 Feb 1;37(4):296-304. doi: 10.1200/JCO.18.00885. Epub 2018 Dec 18.

77. Reproducibility and Transportability of the Absence of Incremental Infectious Adverse Events in Patients With Higher Anti-TNF Drug Levels.

Giannini EG, Demarzo MG, Bodini G. Inflamm Bowel Dis. 2019 Jun 18;25(7):e73. doi: 10.1093/ibd/izy390. No abstract available.

78. Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals.

Crespi M, Demarzo MG, Brunacci M, Pellegatta G, Ferrando F, Ballestrero A, Grillo F, Savarino V, Giannini EG. Ann Hepatol. 2018 Oct 16;17(6):1072-1077. doi: 10.5604/01.3001.0012.7208. Review.

79. Micro-elimination of hepatitis C virus infection in  $\beta$ -Thalassaemia major patients: Positively moving towards the World Health Organisation 2030 eradication goal.

Giannini EG, Aghemo A. Dig Liver Dis. 2019 Apr;51(4):568-569. doi: 10.1016/j.dld.2019.01.001. Epub 2019 Jan 14. No abstract available.

80. Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria.

Ravaioli M, Odaldi F, Cucchetti A, Trevisani F, Piscaglia F, De Pace V, Bertuzzo VR, Neri F, Golfieri R, Cappelli A, D'Errico A, Cescon M, Del Gaudio M, Fallani G, Siniscalchi A,

Morelli MC, Ciccarese F, Di Marco M, Farinati F, Giannini EG, Pinna AD. *Sci Rep*. 2019 Mar 7;9(1):3781. doi: 10.1038/s41598-019-40543-4.

81. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study.

Vitale A, Farinati F, Pawlik TM, Frigo AC, Giannini EG, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Cillo U. *Liver Int*. 2019 Aug;39(8):1478-1489. doi: 10.1111/liv.14154. Epub 2019 Jun 26.

82. A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease.

Bodini G, Zanella C, Crespi M, Lo Pumo S, Demarzo MG, Savarino E, Savarino V, Giannini EG. *Nutrition*. 2019 Nov - Dec;67-68:110542. doi: 10.1016/j.nut.2019.06.023. Epub 2019 Jul 1.

83. Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy.

Petta S, Rini F, Calvaruso V, Cammà C, Ciminnisi S, Di Marco V, Giannini EG, Grimaudo S, Maria Pipitone R, Craxì A. *Liver Int*. 2020 Mar;40(3):530-538. doi: 10.1111/liv.14250. Epub 2019 Sep 25.

84. Regression of Fibrosis After Direct-acting Antivirals Treatment of Patients with Hepatitis C Virus Cirrhosis: Transposability to Nondecompensated Patients.

85. Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F. *J Clin Exp Hepatol*. 2019 Jul-Aug;9(4):546. doi: 10.1016/j.jceh.2018.10.007. Epub 2018 Nov 8. No abstract available.

86. High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease.

87. Bodini G, Demarzo MG, Saracco M, Coppo C, De Maria C, Baldissarro I, Savarino E, Savarino V, Giannini EG. *Scand J Gastroenterol*. 2019 Oct;54(10):1220-1225. doi: 10.1080/00365521.2019.1666914. Epub 2019 Sep 25.

88. Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics.

89. Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, Melandro F, Russo FP, Miele L, Viganò L, Burra P, Giannini EG; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. *Cancers (Basel)*. 2019 Oct 15;11(10). pii: E1568. doi: 10.3390/cancers11101568. Review.

90. Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice.
91. Giannini EG, Aglitti A, Borzio M, Gambato M, Guarino M, Iavarone M, Lai Q, Levi Sandri GB, Melandro F, Morisco F, Ponziani FR, Rendina M, Russo FP, Sacco R, Viganò M, Vitale A, Trevisani F; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. *Cancers (Basel)*. 2019 Oct 30;11(11). pii: E1689. doi: 10.3390/cancers11111689. Review.
92. Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein.
93. Giannini EG, Trevisani F. *Hepatobiliary Surg Nutr*. 2019 Oct;8(5):515-518. doi: 10.21037/hbsn2019.04.19. No abstract available.
94. Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand.
95. Giannini EG, Bodini G, Furnari M, Marabotto E. *Liver Cancer*. 2019 Nov;8(6):524-526. doi: 10.1159/000501485. Epub 2019 Jul 26. No abstract available.
96. Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered.
97. Plaz Torres MC, Aghemo A, Lleo A, Bodini G, Furnari M, Marabotto E, Miele L, Giannini EG. *Nutrients*. 2019 Dec 5;11(12). pii: E2971. doi: 10.3390/nu11122971. Review.
98. Outcomes of Liver Transplant for Adults With Wilson's Disease.
99. Ferrarese A, Morelli MC, Carrai P, Milana M, Angelico M, Perricone G, Belli LS, Marrone G, Grieco A, Martini S, Manini MA, Faggioli S, Toniutto P, Galeota Lanza A, Bhoori S, Petta S, Giannini EG, Burra P. *Liver Transpl*. 2020 Jan 4. doi: 10.1002/lt.25714. [Epub ahead of print]
100. Hepatitis C virus therapy in children: No one should be left behind. Indolfi G, Giannini EG. *Liver Int*. 2020 Feb;40(2):283-285. doi: 10.1111/liv.14331. No abstract available.
101. Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV.
- 102.

103. Cacciato V, Casagrande E, Bodini G, Furnari M, Marabotto E, Grillo F, Giannini EG.


Ann Hepatol. 2020 Mar - Apr;19(2):222-225. doi: 10.1016/j.aohep.2019.11.006. Epub 2019 Dec 5.

CAPITOLI DI LIBRI

1. Dulbecco P, **Giannini EG**, Savarino V. Prevenzione del danno gastrointestinale: quale alternativa ai FANS?. In Fiorucci S, Morelli A. FANS e COXIB. Prevenzione e Clinica degli Eventi Avversi Gastrointestinali, Cardiovascolari e Renali. (2006. pp. 137-151).
2. Testa R, **Giannini EG**. Malattie epatiche congenite. In Coordinamento Nazionale dei Docenti Universitari di Gastroenterologia. Manuale di Gastroenterologia Unigastro. (2007-2009. pp 341-349).
3. Demelia L, **Giannini EG**. Malattie epatiche congenite. In Coordinamento Nazionale dei Docenti Universitari di Gastroenterologia. Manuale di Gastroenterologia Unigastro. (2010-2012. pp 305-315).
4. **Giannini EG**. Management of varices. In: "Managing the complications of cirrhosis, A practical approach" A. Zaman Editor. Slack Inc. Publisher. pp. 29-60, 2011.

Autorizzo il trattamento dei miei dati personali ai sensi del Codice Privacy e del GDPR 2016/679 – Codice in materia di protezione dei dati personali (facoltativo)".

Firma

A handwritten signature in black ink, appearing to be 'EG', written over a horizontal line.

Genova, 9 Marzo 2020